Northland raised the firm’s price target on Brainsway (BWAY) to $30 from $23 and keeps an Outperform rating on the shares. The firm believes that its FDA-approved SWIFT accelerated protocol and its strategic partnerships will boost both near and long-term prospects, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Wins Draft Highmark Coverage for Accelerated Deep TMS Depression Protocol
- Brainsway announces draft coverage policy from Highmark for Deep TMS
- BrainsWay Highlights FDA Approval of Neurolief’s At-Home Proliv Rx Device for Treatment-Resistant Depression
- Brainsway announces U.S. FDA granted PMA for Neurolief’s ProlivRx system
- BrainsWay Wins First Insurer Coverage for Accelerated Deep TMS Depression Protocol